LBRX (LB Pharmaceuticals) Additional Paid-In Capital: $532.34 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LBRX LB Pharmaceuticals Inc LBRX
12 GF Score
Price $42.99
! 1 Warning Sign
View Full Analysis

What is LB Pharmaceuticals Additional Paid-In Capital?

LB Pharmaceuticals LBRX +1.62% 12 Additional Paid-In Capital is $532.34 Mil as of Jun. 2026. GuruFocus rates LBRX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.


LB Pharmaceuticals's quarterly additional paid-in capital increased from Dec. 2025 ($430.67 Mil) to Mar. 2026 ($527.06 Mil) and increased from Mar. 2026 ($527.06 Mil) to Jun. 2026 ($532.34 Mil).

LB Pharmaceuticals's annual additional paid-in capital increased from Dec. 2023 ($6.47 Mil) to Dec. 2024 ($9.66 Mil) and increased from Dec. 2024 ($9.66 Mil) to Dec. 2025 ($430.67 Mil).

LB Pharmaceuticals Additional Paid-In Capital Related Terms

LB Pharmaceuticals Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for LB Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LB Pharmaceuticals Additional Paid-In Capital Chart

LB Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
6.13 6.47 9.66 430.67

LB Pharmaceuticals Quarterly Data
Mar23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - 428.33 430.67 527.06 532.34
LBRX
12GF Score
LB Pharmaceuticals Inc LBRX
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LB Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $532.34 Mil mean?
LB Pharmaceuticals (LBRX) has a Additional Paid-In Capital of $532.34 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on LB Pharmaceuticals and its competitors.
Is LB Pharmaceuticals' Additional Paid-In Capital too high?
LB Pharmaceuticals' current Additional Paid-In Capital is $532.34 Mil. Overall, LB Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LB Pharmaceuticals' Additional Paid-In Capital compare to AVLN and LTGO?
LB Pharmaceuticals' Additional Paid-In Capital of $532.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on LB Pharmaceuticals and its competitors. LB Pharmaceuticals's current Additional Paid-In Capital is $532.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LB Pharmaceuticals stock overvalued right now?
LB Pharmaceuticals (LBRX) has a current Additional Paid-In Capital of $532.34 Mil. The current Additional Paid-In Capital is $532.34 Mil. LB Pharmaceuticals' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For LB Pharmaceuticals (LBRX), the current Additional Paid-In Capital is $532.34 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LB Pharmaceuticals Business Description

Address One Pennsylvania Plaza, Suite 1025, New York, NY, USA, 10119
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
12GF Score

Get the complete analysis for LBRX

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.99
Price